Every article on this site is written by AI from official sources and checked by a second AI. How it works
Final ruleTook effect Oct. 20, 2025

Microbiology Devices; Reclassification of Antigen, Antibody, and Nucleic Acid-Based Hepatitis B Virus Assay Devices

Built by the Tribune's code from the Federal Register. No AI wrote this page. Published in the Federal Register Sept. 18, 2025. Document 2025-18082. Updated Nov. 19, 2026.

What it does

The Food and Drug Administration (FDA) is issuing a final order reclassifying qualitative hepatitis B virus (HBV) antigen assays (product code LOM), HBV antibody assays (product code LOM), and quantitative HBV nucleic acid-based assays (product code MKT), all of which are postamendments class III devices, into class II (special controls), subject to premarket notification. FDA is also establishing the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of these device types.

The Food and Drug Administration's summary, as published in the Federal Register.

What changed in the regulation

1 part of Title 21 of the Code of Federal Regulations:

21 CFR 866

Wording on eCFR: the day before it took effect and from the day it took effect (first part listed).

Compared with

The Food and Drug Administration has published 103 final rules in 2026 so far, compared with 68 in all of 2025.

Counted by the Tribune from Federal Register records since Jan. 1, 2025.

What happens next and when

This order is effective October 20, 2025. See further discussion in Section IV, "Implementation Strategy."

The agency's dates, word for word.

Document number2025-18082
ActionFinal amendment; final order.
AgenciesHealth and Human Services Department; Food and Drug Administration
PublishedSept. 18, 2025
Effective dateOct. 20, 2025
DocketFDA-2024-N-3533

Source: the Federal Register (public domain). The document in the Federal Register